Allogeneic Marrow Transplantation for Myelodysplastic Syndrome with Advanced Disease Morphology: A Phase II Study of Busulfan, Cyclophosphamide, and Total-Body Irradiation and Analysis of Prognostic Factors

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 220-226

  Anderson, Jeanne E ^a   Appelbaum, Frederick R ^b   Schoch, Gary ^b   Gooley, Ted ^b   Anasetti, Claudio ^b   Bensinger, William I ^b   Bryant, Eileen ^b   Buckner, C Dean ^b   Chauncey, Thomas ^b   Clift, Reginald A ^b   Deeg, H Joachim ^b   Doney, Kristine ^b   Flowers, Mary ^b   Hansen, John A ^b   Martin, Paul J ^b   Matthews, Dana C ^b   Nash, Richard A ^b   Sanders, Jean E ^b   Shulman, Howard ^b   Sullivan, Keith M ^b   Witherspoon, Robert P ^b   Storb, Rainer ^b   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; INFECTION; KARYOTYPING; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0030069853     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.220     Document Type: Article

References (24)

1. Jacobs A: Genetic lesions in preleukaemia. Leukemia 5:277-282, 1991
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
3. Ganser A, Hoelzer D: Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:607-618, 1992
4. Sanz GF, Sanz MA, Vallespi T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989
5. Cheson BD: The myelodysplastic syndromes: Current approaches to therapy. Ann Intern Med 112:932-941, 1990
6. Anderson JE, Appelbaum FR, Fisher LD, et al: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677-681, 1993
7. Anderson JE, Appelbaum FR, Storb R: An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymph 17:95-99, 1995
8. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194-2199, 1993
9. Nevill TJ, Shepherd JD, Reece DE, et al: Treatment of myelodysplastic syndrome with busulfan-cydophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10:445-450, 1992
10. Sutton L, Leblond V, Le Maignan C, et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: Outcome of 86 patients. Bone Marrow Transplant 7:39, 1991 (suppl 2)
11. DeWitte T, Zwaan F, Hermans J, et al: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74:151-155, 1990
12. Longmore G, Guinan EC, Weinstein HJ, et al: Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. J Clin Oncol 8:1707-1714, 1990
13. O'Donnell MR, Nademanee AP, Snyder DS, et al: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5:1822-1826, 1987
14. Petersen FB, Buckner CD, Appelbaum FR, et al: Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: A phase I study. Bone Marrow Transplant 4:617-623, 1989
15. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735, 1986
16. Nash RA, Etzioni R, Storb R, et al: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single center study. Blood 85:3746-3753, 1995
17. Santos GW, Tutschka PJ, Brookmeyer R, et al: Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1:21-28, 1987
18. Anasetti C, Hansen JA, Waldmann RA, et al: Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 84:1320-1327, 1994
19. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76:1037-1045, 1990
20. Fisher LD, Van Belle G: Biostatistics: Methodology for the Health Sciences. New York, NY, Wiley, 1993
21. Cox DR, Oakes D: Analysis of Survival Data. London, United Kingdom, Chapman & Hall, 1984
22. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867-1871, 1990
23. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 77:1660-1665, 1991
24. Lynch MHE, Petersen FB, Appelbaum FR, et al: Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 15:59-64, 1995